68 filings
8-K
CNSP
Cns Pharmaceuticals Inc
16 May 24
Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure
10:56am
8-K
CNSP
Cns Pharmaceuticals Inc
7 May 24
Other Events
5:00pm
8-K
CNSP
Cns Pharmaceuticals Inc
3 May 24
Departure of Directors or Certain Officers
4:26pm
8-K
CNSP
Cns Pharmaceuticals Inc
12 Apr 24
Regulation FD Disclosure
6:37pm
8-K
CNSP
Cns Pharmaceuticals Inc
1 Apr 24
Berubicin study enrollment completed; Topline data expected in first half of 2025
5:01pm
8-K
imr rgcnq4l
27 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:15pm
8-K
1rbz7 kjhy
21 Feb 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm
8-K
pb72tje3
2 Feb 24
Entry into a Material Definitive Agreement
5:00pm
8-K
cj0awkl
23 Jan 24
Departure of Directors or Certain Officers
4:01pm
8-K
n4uxw3 jf
21 Dec 23
Regulation FD Disclosure
9:15am
8-K
eybws04 bd
18 Dec 23
CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy
8:36am
8-K
hz4uf95o8sn46
15 Nov 23
Results of Operations and Financial Condition
8:00am
8-K
19cuxvm 1px5
18 Oct 23
Regulation FD Disclosure
9:00am
8-K
ibq3rbzhu0e5ens33
17 Oct 23
Entry into a Material Definitive Agreement
8:00am
8-K
s0mber hnlkip2
18 Sep 23
Submission of Matters to a Vote of Security Holders
7:51pm
8-K
1us3m
18 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:25pm
8-K
k4vgxxb8
15 Aug 23
Amendments to Articles of Incorporation or Bylaws
8:30am
8-K
d8dhpnk0
14 Aug 23
CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Continued rapid pace of enrollment with ~75% of expected patients now enrolled
9:25am
8-K
gi6nbg
15 May 23
CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides
8:36am
8-K
gfjci rve
8 May 23
Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors
8:45am